Rating Rationale
September 07, 2022 | Mumbai
Balaxi Pharmaceuticals Limited
'CRISIL BBB+/Stable' assigned to Bank Debt
 
Rating Action
Total Bank Loan Facilities RatedRs.50 Crore
Long Term RatingCRISIL BBB+/Stable (Assigned)
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has assigned its CRISIL BBB+/Stable rating to the long-term bank facilities of Balaxi Pharmaceuticals Limited (BPL, part of Balaxi group).

 

The rating reflects BPL's established market position in Angola and Latin America, extensive experience of the promoters, and healthy financial profile. These strengths are partially offset by its working capital-intensive operations, revenue concentration risks and Risks related to the upcoming capex plans.

Analytical Approach

CRISIL Ratings has combined the business and financial risk profiles of BPL, along with its wholly owned subsidiary and step-down subsidiaries. This is because all these entities, collectively referred to as Balaxi group, are in the same line of business, have common promoters and strong business and financial linkages.

 

Please refer Annexure - List of Entities Consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description

Strengths:

Established market position in Angola and Latin America: The group has an established market position in the countries like Angola, Dominican Republic, and Guatemala. Benefits from the recognition of products and brand by doctors, pharmacists, and healthcare professionals across these markets should continue over the medium term. Supported by the same, the group has reported revenue of Rs.279.42 crore in Fiscal 2022.

 

Extensive experience of the promoters: The promoter Mr. Ashish Maheshwari has experience of around two decades in the pharmaceuticals industry, their strong understanding of market dynamics and healthy relationships with suppliers and customers should continue to support the business. The company will continue to benefit from the experience and expertise from its management team and leverage its customer relationships.

 

Healthy financial profile: BPL’s financial risk profile is healthy marked by a comfortable Net worth, healthy capital structure and robust debt protection metrics. Capital structure is healthy marked by gearing and total outside liabilities to total tangible net worth (TOL/TNW) of 0.04 time and 0.68 time, respectively, as on 31st March 2022 while net worth is comfortable at Rs.89.83 crore. Debt protection metrics are robust marked by Interest coverage ratio (ICR) of 73.30 times and Net cash accruals to adjusted debt ratio of 13.24 times in Fiscal 2022.

 

Weakness:

Working capital intensive operations: Operations are working capital intensive as reflected in gross current assets (GCA) of 181 days as of March 2022 owing to inventory days of around 150 to 180 days. This is supported by moderate support from creditors of around 90 days.

 

Revenue concentration risks: More than 75% of revenue coming from Angola, the company remains vulnerable to economic uncertainties in the region and volatility in currency rates.

 

Risks related to the upcoming capex plans: The group is taking up a project to set up a New manufacturing unit in fiscal 2023 at an estimated cost of around Rs.95 crore, which will be partly funded via debt of Rs 40 crore. The balance requirement will be met through internal accruals and promoters’ contribution. Completion of the capex within budgeted costs, timely commencement of commercial operations and offtake from the same will remain key monitorables.

Liquidity: Adequate

Cash accruals are expected to be over Rs 48-52 crore which are sufficient against negligible debt obligation over the medium term. In addition, it will act as cushion to the liquidity of the company. Current ratio is healthy at 2.27 times on March31, 2022. Low gearing and comfortable net worth support its financial flexibility and provides the financial cushion available in case of any adverse conditions or downturn in the business. Newly availed working capital limit of Rs.30 crore will support the liquidity

Outlook: Stable

CRISIL Ratings believe BPL will continue to benefit from the extensive experience of its promoter, and established relationships with clients.

Rating Sensitivity Factors

Upward factor

  • Sustained improvement in scale of operation and sustenance of operating margin at over 18%, leading to higher cash accruals while improving revenue diversity
  • Sustenance of healthy financial risk profile

 

Downward factor

  • Decline in scale of operations leading to leading to net cash accrual lower than Rs. 35 crores
  • Large debt-funded capital expenditure or substantial increase in its working capital requirements thus weakening its liquidity & financial profile

About the Group

Balaxi group is an IPR based pharmaceuticals player supplying to Angola and Latin America market under the brand ‘Balaxi’. The group is also involved in branding and selling to FMCG products and Ancillary products. It is promoted by Mr. Ashish Maheshwari and family.

Key Financial Indicators (Consolidated)

As on/for the period ended March 31

Unit

2022

2021

Operating income

Rs.Crore

279.42

231.51

Reported profit after tax

Rs.Crore

47.69

38.14

PAT margins

%

17.06

16.47

Adjusted Debt/Adjusted Networth

Times

0.04

0.06

Interest coverage

Times

73.30

161.41

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon rate (%)

Maturity date

Issue size (Rs.Cr)

Complexity

Levels

Rating assigned with outlook

NA

Proposed Long Term Bank Loan Facility

NA

NA

NA

20

NA

CRISIL BBB+/Stable

NA

Working Capital Facility

NA

NA

NA

30

NA

CRISIL BBB+/Stable

Annexure - List of Entities Consolidated

Names of Entities Consolidated

Extent of Consolidation

Rationale for Consolidation

Balaxi Global DMCC, Dubai

Full

Subsidiary

Balaxi Healthcare Dominica SRL, Dominican Republic

Full

Step down Subsidiary

Balaxi Healthcare Guatemala S.A., Guatemala

Full

Step down Subsidiary

Balaxi Heathcare Honduras S. DE R.L

Full

Step down Subsidiary

Balaxi Heathcare El Salvador SA DE

Full

Step down Subsidiary

Balaxi Heathcare Angola LDA

Full

Step down Subsidiary

Balaxi Heathcare Centrafrique SARL

Full

Step down Subsidiary

Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 50.0 CRISIL BBB+/Stable   --   --   --   -- --
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Proposed Long Term Bank Loan Facility 20 Not Applicable CRISIL BBB+/Stable
Working Capital Facility 30 Kotak Mahindra Bank Limited CRISIL BBB+/Stable

This Annexure has been updated on 07-Sep-2022 in line with the lender-wise facility details as on 07-Sep-2022 received from the rated entity.

Criteria Details
Links to related criteria
CRISILs Bank Loan Ratings
The Rating Process
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Understanding CRISILs Ratings and Rating Scales
CRISILs Criteria for Consolidation

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Himank Sharma
Director
CRISIL Ratings Limited
D:+91 124 672 2152
Himank.Sharma@crisil.com


Jayashree Nandakumar
Associate Director
CRISIL Ratings Limited
D:+91 44 4226 3623
Jayashree.Nandakumar@crisil.com


Dinesh Kumar
Rating Analyst
CRISIL Ratings Limited
B:+91 44 4226 3600
Dinesh.Kumar@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL’s privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale (‘report’) that is provided by CRISIL Ratings Limited (‘CRISIL Ratings’). To avoid doubt, the term ‘report’ includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, ‘CRISIL Ratings Parties’) guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html